TLT-101
Heart Failure
Pre-clinicalActive
Key Facts
About TikkunLev Therapeutics
TikkunLev Therapeutics is a preclinical biotech focused on revolutionizing heart failure treatment through regenerative medicine. Its lead program, TLT-101, is a precision therapy derived from stem cell technology, designed to be administered as a one-time low IV dose and guided by a blood-based biomarker. The company boasts a strong scientific foundation from its co-founder's academic research and has assembled a leadership team and scientific advisory board with deep expertise in cardiology, gene therapy, and biotech development to advance its novel therapeutic paradigm.
View full company profileTherapeutic Areas
Other Heart Failure Drugs
| Drug | Company | Phase |
|---|---|---|
| Cardiac Cell Therapy Program | StemCardia | Pre-clinical |
| NTP42 | ATXA Therapeutics | Preclinical |
| Heart Failure Trial | Clinical Investigation Specialists | Not Specified |
| INPEFA (sotagliflozin) | Lexicon Pharmaceuticals | Approved |
| MyCardia™ | Avery Therapeutics | Pre-clinical |
| Cardiac Assist Device | Second Heart Assist | Pre-clinical |
| Isosorbide Dinitrate/Hydralazine HCl Tablets | i3 Pharmaceuticals | Approved |
| Undisclosed Heart Regeneration Program | Animatus Biosciences | Pre-clinical |
| AFteR Registry | Occlutech | N/A (Registry) |
| biotx.ai Target Discovery Collaboration | HeartBeat.bio | Pre-clinical |
| Surlorian | RyCarma Therapeutics | Phase 2 |
| Coronary Sinus Reduction | Shockwave Medical | Unknown |